Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares
CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s [...]
August 14, 2009
Tags: Anthrax, Anthrax vaccines, Emergent BioSolutions, Health, Infectious disease, Public health, U.S. Food and Drug Administration, Vaccine Posted in: Board of Directors, CEO, Emergent BioSolutions, Shareholders, fuad el-hibri 
No Comments
U.S. Government To Purchase Additional 14.5 Million Doses Of Biothrax® Under New Contract Valued At Up To $404 Million
New contract extends USG’s commitment to purchase BioThrax through 3Q 2011 and is a follow-on to the existing 2007, $448 million contract
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has signed a new, multi-year, firm fixed price contract with the U.S. Department of Health and Human Services (HHS) to supply an additional 14.5 million [...]
July 13, 2009
Tags: Anthrax, Anthrax vaccines, Emergent BioSolutions, Private Securities Litigation Reform Act, Strategic National Stockpile, U.S. Food and Drug Administration, U.S. Government, United States Department of Health and Human Services, United States. Posted in: Uncategorized No Comments
Emergent Biosolutions Acquires Monoclonal Anthrax Product Candidate
Acquisition represents important addition to company’s portfolio of anthrax countermeasures
Emergent BioSolutions Inc. (NYSE: EBS) announced that today it completed the acquisition of a group of anthrax monoclonal antibodies from AVANIR Pharmaceuticals (NASDAQ:AVNR), including Avanir’s lead product candidate, AVP-21D9.
AVP-21D9 is a human monoclonal antibody product candidate that is being developed as an intravenous treatment for patients [...]
July 13, 2009
Tags: Anthrax, Clinical trial, Infectious disease, Monoclonal antibodies, National Institute of Allergy and Infectious Diseases, NIAID, U.S. Food and Drug Administration, United States. Posted in: Uncategorized No Comments
Emergent Biosolutions Submits Proposal In Response To Hhs’ Rfp For Development And Procurement Of A Recombinant Protective Antigen Anthrax Vaccine
The company’s submission provides the U.S. Government with the critical option to select a domestic source to meet planned procurement of 25 million doses of rPA vaccine
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has submitted a proposal in response to a request for proposal (RFP) issued by the U.S. Department of Health and [...]
July 13, 2009
Tags: Clinical trial, Infectious disease, rPA 102, Strategic National Stockpile, U.S. Food and Drug Administration, U.S. Government, United States Department of Health and Human Services, United States., US government Posted in: Uncategorized No Comments
Emergent Biosolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate And Technology
Acquisition positions Emergent to offer the U.S. Government a domestic source for an advanced anthrax vaccine candidate to meet planned procurement of 25 million doses of rPA vaccine.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed the acquisition of all assets and rights related to a recombinant protective antigen (rPA) anthrax vaccine product [...]
July 13, 2009
Tags: Clinical trial, Fort Detrick, Strategic National Stockpile, U.S. Food and Drug Administration, United States Department of Health and Human Services, United States., US government, VaxGen. Posted in: Uncategorized No Comments
Emergent Biosolutions Appoints Dr. W. James Jackson As Chief Scientific Officer
Emergent BioSolutions Inc. (NYSE: EBS) announced today that W. James Jackson, Ph.D., has been appointed chief scientific officer, effective immediately. Dr. Jackson will report directly to Fuad El-Hibri, chairman and chief executive officer.
As CSO, Dr. Jackson will lead the company’s scientific evaluation of new products and technology platforms and will be responsible for building and [...]
July 13, 2009
Tags: Anthrax vaccines, Biotechnology and Pharmaceuticals, Business, Chief executive officer, Infectious disease, Pharmaceutical, Research and development, U.S. Food and Drug Administration, University of Georgia. Posted in: Uncategorized No Comments
Emergent Biosolutions And Ninebio Sdn. Bhd. Announce Joint Venture In Malaysia
Newly formed company to focus on creating critical R&D and manufacturing infrastructure and supplying biodefense countermeasures within Asia and other territories.
January 24, 2008 – Emergent BioSolutions (NYSE: EBS) and Ninebio Sdn. Bhd. (“9Bio”) today announced the formation of a joint venture in Malaysia that will focus on creating critical biologics infrastructure and supplying biodefense countermeasures, [...]
July 13, 2009
Tags: Business, Chief executive officer, Emergent BioSolutions, MALAYSIA, National Institutes of Health, Private Securities Litigation Reform Act, Research and development, SEC, U.S. Food and Drug Administration, United States. Posted in: Uncategorized No Comments